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Abstract 
Myelodysplastic syndrome (MDS) represents
one  of  the  most  challenging  health-related
problems in the elderly. Characterized by dys-
plastic morphology in the bone marrow in asso-
ciation with ineffective hematopoiesis, patho-
physiological causes of this disease are diverse
including genetic abnormalities within myeloid
progenitors, altered epigenetics, and changes
in  the  bone  marrow  microenvironment.  The
concept  that  T-cell  mediated  autoimmunity
contributes to bone marrow failure has been
widely accepted due to hematologic improve-
ment after immunosuppressive therapy (IST)
in a subset of patients. Currently, IST for MDS
primarily  involves  anti-thymocyte  globulin
(ATG)-based  regimens  in  which  responsive-
ness  is  strongly  associated  with  younger
(under 60 years) age at disease onset. In such
cases,  progressive  cytopenia  may  occur  as  a
consequence  of  expanded  self-reactive  CD8+
cytotoxic T lymphocytes (CTLs) that suppress
hematopoietic  progenitors.  Although  most
hematologists agree that IST can offer durable
hematologic  remission  in  younger  patients
with MDS, an international clinical study and a
better understanding of the molecular mecha-
nisms  contributing  to  the  expansion  of  self-
reactive CTLs is crucial. In this review, data
accumulated in the US, Europe, and Asia will be
summarized to provide insight and direction
for a multi-center international trial. 
Overview of myelodysplastic
syndrome
Incidence
Idiopathic  MDS,  as  opposed  to  treatment-
related MDS, occurs with higher incidence in
older individuals in the Western world.1,2 In the
United States, the incidence of MDS from 2001
to 2003 was recently established from popula-
tion-based cancer registries from the National
Cancer Institute’s Surveillance, Epidemiology,
and End Results (SEER) Program and North
American  Association  of  Central  Cancer
Registries  (NAACCR)  databases  and  showed
that the overall incidence is 3.4 per 100,000
(4.5 in men and 2.7 in women). The median
age  at  diagnosis  was  76  years,  with  86%  of
cases  over  60  years  of  age.3,4 Among  racial
groups in the US, white individuals had the
highest incidence rate (3.5/100,000 in Whites)
followed by African Americans (3.0/100,000),
native  Americans  (1.3/100,000)  and  Asians
and  Pacific  Islanders  (2.6/100,000).3,4
Compared to the median age in the US, the
median age of patients with MDS in Asian and
African countries is younger (50 and 60 years
old, respectively).5-11
Current classification systems
To account for heterogeneity within this dis-
ease, in the past few decades the MDS classifi-
cation  system  was  evolved.  In  1982,  the
French-American-British  (FAB)  classification
system  was  established,12 which  was  later
refined  to  the  World  Health  Organization
(WHO) subtyping.13,14 And recently, the WHO
classification  was  revised  as  the  following
groups: (1) refractory cytopenia with unilin-
eage dysplasia (RCUD) that includes refracto-
ry anemia (RA), refractory neutropenia (RN),
and  refractory  thrombocytopenia  (RT);  (2)
refractory  anemia  with  ringed  sideroblasts
(RARS); (3) refractory anemia with multilin-
eage dysplasia (RCMD); (4) refractory anemia
with excess blasts-1 (RAEB-1); (5) refractory
anemia  with  excess  blasts-2  (RAEB-2);  (6)
myelodysplastic syndrome, unclassified (MDS-
U); (7) MDS associated with isolated del(5q);
and  (8)  refractory  cytopenia  of  childhood
(RCC) as a group of provisional entities. Major
points of the modification are the following:
(1) patients who lack convincing morphologi-
cal  dysplasia  but  have  specific  MDS-related
cytogenetic  abnormalities  have  presumptive
evidence of MDS; (2) refractory neutropenia
and thrombocytopenia are added, along with
refractory anemia, to the category of RCUD;
(3) patients with dysplasia and <5% bone mar-
row  (BM)  blasts  but  ≥2%  in  the  peripheral
blood (PB) are classified RAEB1, and (4) a pro-
visional  entity,  Refractory  Cytopenia  of
Childhood (RCC) has been added; distinguish-
ing RCC from aplastic anemia (AA) can be dif-
ficult. 
The  International  Prognostic  Scoring
System (IPSS) was introduced as a universal
risk stratification system for treatment deci-
sion making.1 IPSS considers the percentage
of marrow blasts, the number of cytopenias,
and bone marrow cytogenetics to predict sur-
vival  and  progression  to  AML.  Patients  with
untreated MDS are categorized into four IPSS
prognostic  risk  groups;  low,  intermediate-1
(Int-1), intermediate-2 (Int-2), and high-risk
with median survival estimates of 5.7, 3.5, 1.2,
and 0.4 years, respectively. The risk of AML
evolution of 25% of patients was determined to
be 9.4 (low-risk), 3.3 (Int-1), 1.1 (Int-2), and
0.2 (high-risk) years, respectively. 
The IPSS system was designed to be applied
only at diagnosis in patients with de novo MDS
and may not be suitable for serial assessment
of patients whose disease evolves over time.
Recently, the WHO classification-based prog-
nostic scoring system (WPSS) was proposed to
estimate survival and risk of AML transforma-
tion at multiple time points during the natural
course of MDS. The WPSS score integrates the
three  most  important  prognostic  factors  in
MDS patients classified according to WHO cri-
teria: karyotype, WHO subgroup, and require-
ment for RBC transfusion as an indicator of
symptomatic anemia. In contrast with the four
risk groups identified by the IPSS, the WPSS
stratifies MDS patients into five different risk
categories: very low (score=0), low (1), inter-
mediate (2), high (3-4), or very high (5-6).
Significant differences can be seen among the
five groups in overall survival (P<0.0001) and
risk of AML transformation (P<0.0001). In an
independent  cohort  of  patients  with  MDS,
median survival ranged from 140 months for
patients with a score of 0 to ten months for
those with a score of 5 or more. The most sig-
nificant improvement in prognostic stratifica-
tion  compared  with  IPSS  is  observed  in
patients without excess blasts, primarily due to
the strong impact of the number of dysplastic
lineages and transfusion dependency. 
Kantarjian et  al.  also  proposed  a  new  risk
model in MDS that accounts for events not con-
sidered  in  the  original  IPSS.  They  analyzed
1,915 patients with MDS including secondary
MDS and CMML. Only 507 patients (26%) could
be classified by the IPSS.15 A multivariate sur-
vival analysis identified a myelodysplastic syn-
drome risk score (Table 1). Four prognostic risk
groups are proposed for the new risk model: (1)
low-risk (score 0-4: 16% of patients), in which
patients have an estimated median survival of
54 months and a 3-year survival rate of 63%; (2)
intermediate-1 risk (score 5-6; 24% of patients),
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in which patients have an estimated median
survival of 25 months and a 3-year survival rate
of 34%; (3) intermediate-2 risk (score 7-8; 24%
of patients), in which patients have an estimat-
ed median survival of 14 months and a 3-year
survival rate of 16%; and (4) high-risk (score
≥9; 36% of patients), in which patients have an
estimated median survival of six months and a
3-year survival rate of 4%. The proposed model
was validated in the separate test group and
proved to be applicable at any time during the
course of disease.
Immunological pathophysiology
Overview
Various pathological disturbances have been
linked to the etiology of MDS including genes
that  are  involved  in  cell  cycle  control,  DNA
repair, gene transcription, telomere length and
other  chromosome  abnormalities,  mitotic
checkpoints, cell growth, apoptosis, and cell dif-
ferentiation and maturation.16-21 In response to
this  pleiotropic  biology,  several  therapeutic
options have been developed in recent years
including  azacitidine,22 decitabine,23,24 and
lenalidomide.25-27 Information  from  the  treat-
ment of patients with these newer agents has
influenced the opinion of investigators about
the underlying pathogenesis of MDS.
Dysregulation of immunity in tri-
somy 8 myelodysplastic syndrome
T-cell  immune  dysregulation  is  definitely
associated with bone marrow failure in AA and
large  granular  lymphocyte  leukemia  (LGLL),
which share several clinical features with MDS.
Historically, IST in MDS has been applied in
cases with bone marrow hypocellularity; a clini-
cal feature that is commonly associated with AA
and  observed  in  approximately  15%  of  MDS
cases.28 Numerous  abnormalities  in  immune
function  appear  to  contribute  to  impaired
hematopoiesis including elevated plasma levels
of several cytokines such as tumor necrosis fac-
tor-alpha  (TNF-α)29,30 and  interferon-gamma
(IFN-γ),31 which are well-known contributors to
AA pathogenesis. Many investigators have now
confirmed that cytopenias are corrected by T-
cell  depleting  immunotherapy  in  some  MDS
patients.32-35 From data in vitro and in vivo, the
current consensus is that a few autologous T
cells  directly  suppress  erythroid  (CFU-E)  and
granulocytic (CFU-GM) progenitor cell differen-
tiation.36
A hallmark of T-cell dominant autoimmunity
is the expansion of T-cell clones with restricted
diversity that possess a limited T-cell receptor
(TCR)-Vβ repertoire.  Limitation  in  TCR-Vβ
complementary-determining  region  3  (CDR3)
diversity and clonal expansion of T cells in asso-
ciation with bone marrow suppression suggests
that  escape  from  peripheral  tolerance  and
recognition of self-antigens may contribute to
suppressive  hematopoiesis.  Peripheral  toler-
ance may be averted by chromosomal aberra-
tions,  or  other  disease-specific  changes  that
occur  in  the  microenvironment.  While  the
mechanisms that underlie the generation of T-
cell clonal expansion remains elusive, Epling-
Burnette et al. showed that clonal T-cell expan-
sion occurs in 50% of MDS patients compared to
5% in healthy individuals of a similar age range.
Importantly, T-cell expansion was not restricted
to specific IPSS, WHO subtypes, age, transfu-
sion history, or karyotypes37 implying that T-cell
expansion  occurs  commonly  among  all  MDS
prognostic  subgroups.  Sloand  et  al. has  con-
firmed the identity of one antigen that drives
abnormal  T-cell  clonal  expansion  that  con-
tributes to impaired hematopoiesis in patients
with a trisomy 8 cytogenetic abnormality.38 This
abnormality is seen in both MDS and AA and is
associated with favorable prognosis. Indicative
of underlying immune pathology, patients with
trisomy  8  display  an  increased  frequency  of
response to IST compared to patients with other
chromosomal abnormalities.38 Clonally expand-
ed CD8+ cells with reduced TCR-Vβ repertoire
diversity and direct cytotoxicity of autologous
trisomy  8  hematopoietic  progenitors  was
observed  in  vitro.39 CD8+ T-cell  self-reactivity
was not observed in MDS patients with 5q- and
monosomy  7  chromosomal  abnormalities.39
Bone  marrow  progenitors  with  a  trisomy  8
abnormality were more sensitive to Fas-mediat-
ed apoptosis and more likely to express activat-
ed  apoptotic  markers  such  as  caspases.40 In
addition, a small number of trisomy 8 cells were
present in bone marrow by fluorescence in situ
hybridization  (FISH)  long  before  cytogenetic
conversion by standard metaphase karyotyping,
suggesting that trisomy 8 aneuploidy may be an
early event in MDS. It was hypothesized that the
CTL response was initially triggered by abnor-
mal stem cells but the bone marrow failure was
subsequently  mediated  by  a  ‘bystander’  CTL
response  against  healthy  hematopoietic  cells.
The  Wilms’  tumor-1  (WT1)  protein,  which  is
localized  on  chromosome  8,  and  thus  over-
expressed in MDS patients with trisomy 8, rep-
resents  a  well-defined  target  of  self-reactive
CTLs in IST responsive patients.41 T cells may
undergo TCR-dependent activation in response
to the overproduction of the WT1 antigen, differ-
entiate into effector and memory cells that elicit
a WT1-specific CTL response, and as a conse-
quence lead to bone marrow failure through the
destruction  of  both  trisomy  8  and  normal
hematopoietic  progenitors  (HPCs).  Long-term
survival of WT1-specific T cells has previously
been linked to the expression of c-myc, CD1, and
survivin (an inhibitor of apoptosis).38,42
While the linkage between immune-mediat-
ed pathogenesis and trisomy 8 is mechanisti-
cally established, this chromosomal abnormal-
ity occurs in only 5-10% of MDS patients and
more  often  in  those  that  evolve  from  AA.
Response to IST is clearly not restricted to this
limited  subpopulation  of  MDS  patients  sug-
gesting that the mechanism of immune patho-
genesis in patients without trisomy 8 must be
explored  further.  The  role  of  aberrant  T-cell
homeostasis  and  the  relationship  between
skewed TCR-Vβ repertoires in patients with-
out a trisomy 8 is yet to be defined.  In summa-
ry, distinguishing features of trisomy 8 posi-
tive bone marrow cells may represent a distinct
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Table 1. Simplified myelodysplastic syndrome risk score (0-15 Points).
Prognostic Factor Coefficient Points
Performance status
≥2 0,267 2
Age, y
60-64 0.179 1
≥65 0.336 2
Platelets, x109/L
<30 0.418 3
30-49 0.270 2
50-199 0.184 1
Hemoblobin <12 g/dL 0.274 2
Bone marrow blasts, %
5-10 0.222 1
11-29 0.260 2
WBC >20x109/L 0.258 2
Karyotype: Chromosome 7 abnormality 0.479 3
or complex ≥3 abnormalities
Prior transfusion, yes 0.107 1
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pathophysiological entity associated with the
direct  stimulation  of  CD8+ T  cells  that  may
receive benefit from IST (Figure 1).  
Search for predictive biomarkers of
immune pathophysiology
Since  the  mechanisms  contributing  to
immune pathophysiology and patient selection
criteria  for  IST  remain  elusive  in  patients
without trisomy 8, a search for predictive bio-
markers is critically needed. Classic paroxys-
mal  nocturnal  hemoglobinuria  (PNH)  is  an
acquired disease characterized by intravascu-
lar  hemolysis  that  results  from  the  clonal
expansion  of  PIG-A mutant  hematopoietic
stem cells (HSCs) producing blood cells defi-
cient in glycosylphosphatidylinositol-anchored
proteins (GPI-AP), such as CD55 (decay accel-
erating  factor,  DAF)  and  CD59  (membrane
inhibitor of reactive lysis, MIRL). Such GPI-AP
deficient (paroxysmal nocturnal hemoglobin-
uria (PNH) - type) cells are often detectable in
the peripheral blood of patients with bone mar-
row failure syndromes including AA and RA as
defined by the FAB group.43-45 How PNH-type
cells arise and increase in patients with BM
failure remains obscure. PIG-A mutation itself
does  not  confer  a  proliferative  advantage  to
HSCs. The most widely accepted mechanism
for  clonal  expansion  of  PNH-type  cells  in
patients with BM failure is the “escape hypoth-
esis”, which states that the relative number of
PIG-A mutant  HSCs  increases  by  avoiding
immunological  attacks  by  T  cells  or  NK
cells.46,47 A  murine  study  demonstrated  that
GPI-AP-deficient hematopoietic cells can evade
a T-cell attack due to either the absence of the
target peptide recognized by GPI-AP specific T
cells, or the absence of accessory GPI-AP mole-
cules,  which  are  required  for  HSCs  to  be
attacked by cytotoxic T cells.48In MDS patients,
the  expansion  of  PNH-type  cells  have  been
reported  in  about  20%  of  the  patients  with
lower-risk  MDS  and  that  phenomenon  has
been linked in some studies to IST responsive-
ness.43,44 The assay for PNH detection has not
been standardized across institutions in the
US and differs from that of Europe and Asia
making the association between presence of
PNH-type cells and response to IST difficult to
interpret.49 Standardization  of  the  assay
around the world will likely improve the accu-
racy of this measure as a reliable biomarker of
disease.  
Recently, Zou et al. analyzed the age-adjust-
ed  CD4/CD8  ratio  in  54  MDS  patients  com-
pared  to  37  healthy  controls  which  revealed
that inadequate CD4+rather than expansion of
CD8+ T cells was associated with a lower ratio
in a group that included both lower and higher
risk MDS patients defined by the International
Prognostic Scoring System (IPSS).50 Inversion
of the CD4/CD8 ratio was strongly associated
with response to therapy (P<0.001). The loss
of  CD4-cells  was  inversely  correlated  to  the
proliferative T-cell index before treatment in
IST-responsive patients suggesting that prolif-
eration and accelerated CD4+ T-cell turnover
may be important in disease pathogenesis. In
many autoimmune diseases, there is a correla-
tion between the loss of CD4+ T cells and the
expansion of autoreactive CD8+ T cells.51 This
abnormality  supersedes  the  simple  loss  of
CD4+ regulatory  T  cells  (Tregs)  from  the
peripheral or tissue compartment. Reduction
in CD4+ T cells may initiate a cytokine-depend-
ent pathway known as “homeostatic prolifera-
tion” in which the interleukin (IL)-2Rγ com-
mon cytokines such as IL-2, IL-7, IL-15 and/or
IL-21 non-specifically expand antigen-specific
and  self-reactive  T  cells  leading  to  an
increased risk for evasion of peripheral toler-
ance mechanisms leading to autoimmunity.52
Results by Zou et al. are the first to demon-
strate  involvement  of  CD4+ T  cells  and
response to IST. Since the loss of CD4+ T cells
is  strongly  associated  with  impaired  T-cell
homeostasis and accumulation of self-reactive
CD8+ T cells contributes to autoimmunity in
many models of human disease, this mecha-
nism may explain immune pathogenesis from
a global perspective. The highest homeostatic
proliferative index is afforded to T cells with
the highest affinity to self-antigens, explain-
ing not only trisomy 8 autoimmunity, but also
autoimmune pathogenesis in other settings. A
discovery  of  T-cell  receptor  (TCR)  antigen
reactivity in patients with aggressive homeo-
static proliferation, without trisomy 8, is need-
ed.  Kordasti  et  al. recently  showed  that  the
numbers of CD3+ CD4+ IL-17 producing T cells
(Th17)  were  markedly  increased  and  CD4+
CD25high FoxP3+ regulatory  T  cells  (Tregs)
inversely decreased in lower risk MDS com-
pared with higher risk MDS.53 Tregs from MDS
patients suppressed IFN-γ secretion by effector
Article
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Figure 1. Molecular model of T-cell pathogenesis in MDS. Described in this review are the
supporting data that link T-cell abnormalities to multiple abnormal events that include
apoptotic response and the presence of inflammation in the bone marrow microenviron-
ment. The mechanism controlling the expansion of self-reactive CD8+ T-cells appears to
be two fold described by two models (DIRECT and INDIRECT); 1) there may be direct
activation of CD8+ T cells in response to abnormally expressed bone marrow antigens as
exemplified by patients with trisomy 8, and 2) there may be expansion of destructive CD8
T cells due to homeostatic cytokines of the IL-2Rβγcommon cytokines which include IL-
7, IL-2, IL-15, and IL-21. From previous results, lymphopenia-associated autoimmunity
has been linked to antigen-specific CD8+ T cells  with variable self- antigen reactivity.
Survival advantage and clonal expansion dominates from CD8+ self-reactive T cells that
respond to antigen in the context of self-MHC class I bypassing peripheral tolerance
mechanisms. Results suggest that self-reactive CD8+ T-cells are involved in the suppres-
sion of bone marrow progenitors through direct cytotoxicity of the MDS clones such as
trisomy 8+ HPCs or the release of cytokines such as TNFα and IFNγ. There is also evi-
dence that depletion of CD4+ regulatory T cells (Tregs) and accumulation of IL-17-secret-
ing CD4+ T cells (Th17) may be imbalanced. Evidence supports the role of these T-cell
abnormalities  in  cytopenias  and  increased  apoptosis  observed  in  lower-risk  MDS.
HPC=Hematopoietic Progenitor Cells, WT1=Wilms’ tumor 1 antigen.[page 4] [Hematology Reports 2010; 2:e1]
CD4+ T cells but had no effect on IL-17 produc-
tion. In addition, the serum levels of IL-7, IL-
12, RANTES and IFN-γ are significantly elevat-
ed in lower risk MDS, while inhibitory factors,
such as IL-10 and soluble IL-2 receptor, are sig-
nificantly  higher  in  high-risk  disease.  They
concluded  that  the  unfavorable Th17:Tregs
ratio in low-risk MDS may explain the higher
risk  of  autoimmunity  and  the  improved
response  to  immune  suppression  in  patients
with low-risk MDS compared to those with high-
risk disease.53 In general, more work should be
performed to determine the precise relationship
between CD4+ T cells, HLA DR15, and homeo-
static turnover as an alternative mechanism of
autoimmunity in MDS (Figure 1).
Therapy
Response criteria
In line with changes in the various classifi-
cation  systems,  therapeutic  response  stan-
dards  have  also  evolved.  In  2000,  the
International  Working  Group  (IWG)  recom-
mended  specific  criteria  for  response  that
defined  four  treatment  goals  including:  (1)
treatment that alters the natural history of the
disease; (2) cytogenetic response; (3) hemato-
logic improvement (HI); and (4) quality of life
(QOL).54 The HI responses are particularly rel-
evant  in  patients  treated  with  IST  since
patients generally have lower risk disease, pos-
sess fewer bone marrow blasts, and suffer from
long-standing cytopenia. The IWG criteria for
HI define specific response to cytopenia in the
three  hematopoietic  lineages;  erythroid  (HI-
E), platelet (HI-P), and neutrophils (HI-N). In
2006, the IWG proposed modifications to the
response for altering natural history of MDS
and  hematologic  improvement.  These  are
summarized in Table 2.55
ATG based regimens
The goals of MDS therapy are to prolong sur-
vival, delay or prevent AML progression, and to
improve QOL. Although allogeneic hematopoi-
etic stem cell transplantation (HSCT) is the
only curative treatment in MDS, eligibility for
HSCT is limited due to the need for an HLA-
matched donor and the procedure-related co-
morbidities, which is particularly important in
this older patient population.56 With the suc-
cess  of  ATG  in  AA,  there  have  been  several
studies of not only ATG but other ATG-combi-
nation therapies in MDS.57-59
ATG is a mixture of purified polyclonal IgG
from the sera of rabbits (rATG, Thymoglobulin,
Genzyme, Cambridge, MA) or horses (eATG)
immunized  with  human  thymocytes
(Lymphoglobulin,  and  Atgam)  or  the  Jurkat
cell  line  (ATG  Fresenius,  Fresenius  SE,  Bad
Homburg, Germany).60 ATG has diverse effects
on  the  immune  system  including;  (1)  T-cell
depletion in blood and peripheral lymphoid tis-
sues through complement-dependent lysis and
apoptosis;61 (2) modulation of key cell surface
molecules  that  mediate  leukocyte/epithelium
interactions;62 (3) induction of apoptosis in B-
cell lineages;63 (4) interference with dendritic
cell  functional  properties;64 (5)  induction  of
regulatory T65 and natural killer T cells,66 (6)
direct effect on hematopoietic progenitor cell
colony formation from primitive hematopoietic
cells;67 and (7) possibly, elimination of the Fas-
Fas-L interactions.68 Each product has shown
differential effects on the immune microenvi-
ronment  and  homeostasis.  Table  3  summa-
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Table 2. Proposed modified International Working Group response criteria.
For altering natural history of myelodysplastic syndrome
Category Response Criteria (responses must last at least 4 wk)
Complete remission Bone marrow: ≤5% myeloblasts with normal maturation of all cell lines
Persistent dysplasia will be noted
Peripheral blood
Hgb ≥11 g/dL
Platelets ≥100x109/L
Neutrophils ≥1.0x106/L
Blasts 0%
Partial remission All CR criteria if abnormal before treatment expect: one marrow blasts decreased by ≥50%
over pre-treatment but still > 5%
Cellurarity and morphology not relevant
Marrow CR Bone marrow: ≤5% myeloblasts and decrease by ≥50% over treatment
Peripheral blood: if HI responses, they will be noted in addition to marrow CR
Stable disease Failure to achieve at least PR, but no evidence of progression for > 8 wks
For hematologic improvement
Hematologic improvement Response Criteria (responses must last at least 8 wk)
Erythroid response Hgb increase by ≥1.5 g/dL
(pretreatment, < 11 g/dL) Relevant reduction of units of RBC transfusions by an absolute number of at least 4 RBC
transfusions/8 wk compared with the pre-treatment  transfusion number in the previous 8 wk. 
Only RBC transfusions given for a Hgb of ≤9.0 g/dL
pre-treatment will count in the RBC transfusion response evaluation
Platelet response  Absolute increase of ≥30x109/L for the patients starting with >20x109/L platelets
(pre-treatment, < 100x109/L) Increase from <20x109/L to > 20x109/L and by at least 100%
Neutrophil response  At least 100% increase and an absolute increase >0.5x109/L
(pretreatment, < 1.0x109/L)
Progression or relapse after HI At least one of the following:
At least 50% decrement from maximum response levels in granulocytes or platelets
Reduction in Hgb by ≥1.5 g/dL
Transfusion dependence
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rizes  the  results  of  clinical  trials  with  ATG-
based regimens in MDS.
The  first  pilot  study  investigating  ATG  in
patients with MDS was conducted by investiga-
tors at the National Institute of Health (NIH)
in 199777 and the mature data (median follow-
up: 30 months) with a larger sample size was
reported in 2002.69 In this single-arm prospec-
tive study, 61 transfusion-dependent patients
with  MDS  (with  <20%  blasts)  were  treated
with one cycle of eATG (Atgam) at 40 mg/kg/d
for four days. The response criteria were as fol-
lows; (1) independence from transfusion for a
minimum  of  six  weeks  with  a  sustained
increase in hemoglobin, or (2) stable hemoglo-
bin within eight months of ATG treatment, as
measured  from  the  time  the  patient  last
received  a  transfusion  until  reinstitution  of
RBC  transfusions.  Within  eight  months  of
treatment, 21 of 61 patients (34%) no longer
required  red  blood  cell  transfusions.
Independence  from  transfusion  was  main-
tained in 17 of the 21 responders (81%) for a
median  of  36  months  (range  3-72  months).
Ten of 21 patients (47.5%) with severe throm-
bocytopenia had sustained increase in platelet
counts, and 6 of 11 patients (55%) with severe
neutropenia had sustained neutrophil counts
of greater than 1x109 cells/L. The clinical char-
acteristics associated with response included
younger age (Odds ratio, 0.45, P=0.005) and
lower  platelet  counts  (median  68x109/L  vs.
135x109/L, P=0.038).
Saunthararajah et al. reported that human
leukocyte  antigen  (HLA)-DR15  is  overrepre-
sented and is predictive of response to IST in
the patients with MDS.70 It is well known that
HLA-DR15 is overrepresented in patients with
AA  and  PNH.78-80 Sloand  et  al. recently  con-
firmed  these  findings  in  129  MDS  patients
who  received  equine  antithymocyte  globulin
(eATG, Atgam, Pfizer, New York, NY) with or
without  cyclosporine  (CsA,  Novartis,  Basel,
Switzerland) at the National Heart Lung Blood
Institute  (NHLBI).76 Of  129  patients  treated
with  IST,  39  (30%)  achieved  a  hematologic
response  with  a  median  follow-up  of  three
years  (0.03-11.3  years).  Factors  associated
with response to IST were age and HLA-DR15
expression  with  the  strongest  linkage
observed in patients under 61 years of age.
Yazji et al. reported a durable response rate
of  23%  with  at  least  hematologic  improve-
ment.76 In comparison to the initial NIH stud-
ies, a wider spectrum of MDS patients includ-
ing RA/RARS subtypes constituted 54% of the
cohort and only 35% had normal cytogenetics
(vs.  54%  in  studies  by  Molldrem  et  al.68,77)
Another  study  conducted  by  Steensma et  al.
was terminated early due to a lack of clinical
efficacy.72 The early closure was restricted to a
small sample size of 8 subjects. No hematolog-
ic response was observed in any study subject.
Different  factors  might  have  contributed  to
this disappointing result. This cohort shared
unfavorable  characteristics:  all  with  a  Hbg
below 9 g/dL (in comparison to 10 g/dL in all
the  other  studies),  older  age  (range  62-74
years), 6 of 8 patients had RAEB-1 and only 2
of 8 subjects had an RA subtype. Based on the
IPSS, 63% were Int-1 and 36% were Int-2. Four
patients had complex cytogenetics and only 2
had a normal karyotype. Hence, this cohort did
not represent the low-risk MDS population that
was predicted to respond to IST based on NIH
criteria. The small sample size (with 95% con-
fidence interval of 0-37%) could not statistical-
ly exclude the 35-45% hematologic response
reported in the literature. 
In  a  non-randomized,  single-arm  trial  by
Killick  et  al.,81 the  efficacy  of  eATG  (lym-
phoglobulin)  was  studied  in  a  multi-institu-
tional trial. Valuable data with a median follow-
up of 34 months was reported in 2007.75 A total
of 96 patients from centers in the UK (n=65),
Germany (n=13), and Italy (n=18) were treat-
ed  with  one  cycle  of  lymphoglobulin  at
15mg/kg/d  for  five  days.  The  International
Working Group (IWG) response criteria were
applied to evaluate response. In this study, a
total of 40 patients (42%) achieved a hemato-
logic response, of which 30 patients (75%) dis-
played a durable hematologic response lasting
a median duration of 31.5 months (range 6-92
months). In a multivariate analysis, both low
IPSS (P=0.018) and bone marrow hypocellular-
ity (P=0.012) were independent predictors of
response to ATG. In addition, IPSS was the sole
predictor  of  overall  survival,  with  Int-2  and
high-risk patients having a significantly poor-
Article
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Table 3. Clinical trials of ATG based regimen. 
Auther Country N Age  Treatment Formulation RA  HR 
(Published year) ref (Median) (%) (%)
Molldrem (2002)69 US 61 60 eATG Atgam 61 34
Saunthararajah(2002)70 US 72 59 eATG and/or CsA Atgam 46 29
Yazji (2003)71 US 31 59 eATG and CsA Atgam 58 23
Steensma (2003)72 US 8 69 eATG Atgam 25 0
Stadler (2004)73 Germany 35 63 eATG Lymphoglobulin 60 40
rATG  Thymoglobulin 80 27
Broliden (2006)74 Sweden 20 64 rATG and CsA ATG Pharmacia 85 30
Lim (2007)75¶ UK, Germany, 96 (UK, 65: Germany, 56 eATG Lymphoglobulin 84 42
and Italy 13: Italy, 18)
Sloand (2008)§76 US 116 (eATG and CsA, 60 eATG and CsA Atgam 67 48
42: eATG, 74) eATG 24
RA, refractory anemia; HR, hematological response; eATG, equine antithymocyte globulin; rATG, rabbit antithymocyte globulin; CsA, cyclosporine. ¶Responses were defined by IWG ctiteria. §Responses were the
same when the response classification of the IWG criteria was retrospectively applied.
Table 4. Comparison of response to CsA studies.
Auther Country N Age  RA  HR
(Published year) (median) (%) (%)
Jonasova (1998)83 Czech 17 53 94 82
Catalano (2000)84 Italy 9 63 100 55
Atoyebi (2002)85 UK 6 70 100 0
Shimamoto(2003)86¶ Japan 50 55 96 60
Dixit (2005)87 India 19 48 68 58
Chen (2006)88 China 32 46 78 63
Ishikawa (2007)89¶ Japan 20 52 85 53
¶Responses were defined by IWG ctiteria.[page 6] [Hematology Reports 2010; 2:e1]
er survival outcome (P<0.01).
Stadler et al. compared the efficacy of eATG
(lymphoglobulin,  15  mg/kg/d  for  five  days,
n=20) to rATG (thymoglobulin, 3.75 mg/kg/d
for five days, n=15), which is commonly used
for the treatment of AA. There was no signifi-
cant difference between the two ATG products
with  regard  to  either  the  clinically  relevant
responses or frequency of adverse effects.73
Broliden et al. reported the efficacy of ATG
and CsA therapy in MDS patients,74 since this
combination therapy is well known to be more
effective  in  the  patients  with  AA.82 Twenty
patients (17 RA, 3 RAEB) received treatment
with rATG (ATG-Fresenius) plus CsA. The over-
all response rate was 30% (6/20); 3 of the 6
responders  had  a  complete  response.  The
responses lasted 2-58 months, with 2 patients
still being in complete remission at 42 and 58
months, respectively.
CsA usage in MDS
Table 4 summarizes previous clinical trials
of CsA in MDS.83-89 CsA has a strong immuno-
suppressive effect mediated by inactivation of
the protein phosphatase calcineurin, resulting
in  the  inhibition  of  IL-2  gene  activation.90
Inhibition of proliferative CTL expansion may
be critical for autoimmunity in MDS. The first
prospective  trial  with  CsA  was  designed  by
Janasova et al.83 Seventeen cytopenic patients
with MDS were treated and a durable response
was observed in 82%. Of note, 16 out of the 17
subjects  had  the  RA  subtype  but  varying
degrees  of  bone  marrow  cellularity.  Most
patients had a normal karyotype or a single
cytogenetic  abnormality  of  5q-,  which  both
showed positive association with response in
this  study  although  5q-  was  not  associated
with  response  to  ATG  in  the  recent  NHLBI
study.76 The  selection  of  cohorts  with  only
favorable profiles might contribute to the sur-
prisingly high response rate. Catalano et al.
treated 9 patients with RA and also demon-
strated  a  favorable  response.84 In  contrast,
another  study  reported  by  Atoyebi  et  al.85
showed no substantial response to CsA but an
unacceptable toxicity profile. An older median
age of the treatment group  (70 years) may
have impacted the therapeutic response and
likely increased the risk of CsA-related nephro-
toxicity. 
There  have  been  several  reports  of
immunosuppression  use  from  Asian  coun-
tries. A large multicenter study of Japanese
MDS patients was reported by Shimamoto et
al.86 Fifty low-risk MDS patients were treated
with  CsA  (6  mg/kg/d)  with  variable  marrow
cellularity.  Of  these  patients,  30  patients
(60%)  showed  hematologic  improvement.
Comparison of the clinical characteristics in
responders and non-responders demonstrated
that patients with a favorable karyotype, 0 or
0.5  IPSS  score,  and  HLA-DRB1*1501  were
more responsive than patients with interme-
diate or poor risk karyotypes, 1.0 or 1.5 IPSS
score, and other HLA types, respectively. There
was  no  significant  difference  between
response to immunosuppressive therapy and
age, BM cellularity, BM blast percentage, or
dose  and  blood  concentration  of  CsA.
Moreover, they found that bone marrow dys-
plastic  features  were  present  regardless  of
hematologic  response.  This  group  demon-
strated  a  significant  association  between
hematologic  improvement  and  an  inverted
CD4/CD8  ratio  and  TCR-Vβ and  –γ gene
rearrangements  as  biological  predictors  of
response.91 Although correlative studies were
carried out in only a few patients (n=4), these
results corroborate the findings by Zou et al.
using samples from patients at the NHLBI.50
Recently, Ishikawa et al. suggested the signif-
icance of the PNH clone in patients with low-
risk MDS in a prospective study.89 They treat-
ed 20 patients with MDS with CsA (4 mg/kg/d).
Among  19  patients  evaluated,  10  showed
hematologic improvement, most of the toxici-
ty associated with CsA usage was manageable,
and no patient had progressed to AML at the
latest follow-up (median 30 months). A short
duration  of  illness,  RA  with  minimal  bone
marrow  dysplasia,  and  the  presence  of  the
PNH  clone  were  all  significantly  associated
with  a  platelet  response.  A  minority  of  RA
patients who did not possess such predictive
variables  achieved  an  isolated  erythroid
response.
Summary
MDS  is  the  one  of  the  most  challenging
problems in hematology. Although the current
classification  and  prognostic  schemes  have
improved over the past decade, these patholog-
ical classification-based schemes are ineffec-
tive to distinguish pathological diversity and
therapeutic response. Importantly, substantial
clinical benefit is observed with IST treatment
in the US, Europe, and Asia. Response rates of
ATG  therapy  ranged  from  20-40%  and  CsA
response  ranged  from  50-60%  using  IWG
response criteria. ATG therapy, however, has
not been used in Asia and few trials of CsA
therapy have been performed in Western coun-
tries  creating  an  uncertainty  about  whether
there are specific pathobiological features of
the disease in Asia that predispose patients to
IST response or whether CsA therapy is supe-
rior  to  ATG  therapy.  For  the  most  effective
application  of  IST,  definitive  mechanisms  of
pathophysiology  and  biological  predictors  of
response must be established. A large clinical
trial  that  includes  international  centers  and
compares ATG to CsA will clarify the features
associated with immune-mediated MDS. This
study should include not only clinical response
assessment  but  also  correlative  laboratory
analyses of variables shown previously to pre-
dict for hematologic improvement such as T-
cell  clonality,  T-cell  homeostasis,  HLA  type,
microarray  expression  profiling,  and  PNH
analysis. To detect PNH-type cells, a sensitive
assay must be applied to detect small expan-
sions of these cells. In conclusion, the concept
of  autoimmunity  in  MDS  patients  is  widely
accepted but, clarification of the autoimmune
mechanism  contributing  to  bone  marrow
myelodysplasia  and  impaired  hematopoiesis
must  be  obtained.  In  the  future,  the  focus
should be on developing an international coor-
dinated  clinical  trial  to  define  geographical
and therapeutic differences, newer approaches
to immune modulation, and basic studies to
understand  the  pathophysiological  mecha-
nisms.
References
1. Greenberg  P,  Cox  C,  LeBeau  MM,  et  al.
International scoring system for evaluat-
ing  prognosis  in  myelodysplastic  syn-
dromes. Blood 1997;89:2079-88.
2. Estey  E.  Acute  myeloid  leukemia  and
myelodysplastic  syndromes  in  older
patients. J Clin Oncol 2007;25:1908-15.
3. Ma  X,  Does  M,  Raza  A,  Mayne  ST.
Myelodysplastic syndromes: incidence and
survival  in  the  United  States.  Cancer
2007;109:1536-42.
4. Rollison DE, Howlader N, Smith MT, et al.
Epidemiology  of  myelodysplastic  syn-
dromes  and  chronic  myeloproliferative
disorders in the United States, 2001-2004,
using data from the NAACCR and SEER
programs. Blood 2008;112:45-52.
5. Chen B, Zhao WL, Jin J, et al. Clinical and
cytogenetic  features  of  508  Chinese
patients  with  myelodysplastic  syndrome
and  comparison  with  those  in  Western
countries. Leukemia 2005;19:767-75.
6. Lee JH, Shin YR, Lee JS, et al. Application
of  different  prognostic  scoring  systems
and comparison of the FAB and WHO clas-
sifications  in  Korean  patients  with
myelodysplastic  syndrome.  Leukemia.
2003;17:305-13.
7. Toyama K, Ohyashiki K, Yoshida Y, et al.
Clinical  implications  of  chromosomal
abnormalities  in  401  patients  with
myelodysplastic syndromes: a multicentric
study in Japan. Leukemia. 1993;7:499-508.
8. Intragumtornchai  T,  Prayoonwiwat  W,
Swasdikul  D,  et  al.  Myelodysplastic  syn-
dromes in Thailand: a retrospective patho-
logic  and  clinical  analysis  of  117  cases.
Article[Hematology Reports 2010; 2:e1]
Leuk Res 1998;22:453-60.
9. Paydas S, Kocak R. Younger age observa-
tion  in  myelodysplastic  syndrome.  Leuk
Res 1996;20:367.
10. Chatterjee T, Dixit A, Mohapatra M, et al.
Clinical, haematological and histomorpho-
logical profile of adult myelodysplastic syn-
drome. Study of 96 cases in a single insti-
tute. Eur J Haematol 2004;73:93-7.
11. Mukiibi JM, Paul B. Myelodysplastic syn-
dromes (MDS) in Central Africans. Trop
Geogr Med 1994;46:17-9.
12. Bennett JM, Catovsky D, Daniel MT, et al.
Proposals  for  the  classification  of  the
myelodysplastic syndromes. Br J Haematol
1982;51:189-99.
13. Harris NL, Jaffe ES, Diebold J, et al. World
Health Organization classification of neo-
plastic diseases of the hematopoietic and
lymphoid  tissues:  report  of  the  Clinical
Advisory Committee meeting-Airlie House,
Virginia,  November  1997.  J  Clin  Oncol
1999;17:3835-49.
14. Vardiman  JW,  Harris  NL,  Brunning  RD.
The  World  Health  Organization  (WHO)
classification  of  the  myeloid  neoplasms.
Blood 2002;100:2292-302.
15. Kantarjian H, O'Brien S, Ravandi F, et al.
Proposal for a new risk model in myelodys-
plastic syndrome that accounts for events
not  considered  in  the  original  Interna-
tional Prognostic Scoring System. Cancer
2008;113:1351-61.
16. Pfeilstocker M, Karlic H, Nosslinger T, et
al. Myelodysplastic syndromes, aging, and
age:  correlations,  common  mechanisms,
and clinical implications. Leuk Lymphoma
2007;48:1900-9.
17. Rigolin  GM,  Porta  MD,  Bugli  AM,  et  al.
Flow  cytometric  detection  of  accelerated
telomere  shortening  in  myelodysplastic
syndromes: correlations with aetiological
and  clinical-biological  findings.  Eur  J
Haematol 2004;73:351-8.
18. Ohyashiki K, Shay JW, Ohyashiki JH. Lack
of  mutations  of  the  human  telomerase
RNA  gene  (hTERC)  in  myelodysplastic
syndrome. Haematologica 2005;90:691.
19. Hopfer O, Komor M, Koehler IS, et al. DNA
methylation  profiling  of  myelodysplastic
syndrome  hematopoietic  progenitor  cells
during in vitro lineage-specific differenti-
ation. Exp Hematol 2007;35:712-23.
20. Sloand EM, Yong AS, Ramkissoon S, et al.
Granulocyte  colony-stimulating  factor
preferentially  stimulates  proliferation  of
monosomy 7 cells bearing the isoform IV
receptor. Proc Natl Acad Sci USA 2006;103:
14483-8.
21. Zang DY, Goodwin RG, Loken MR, Bryant
E, Deeg HJ. Expression of tumor necrosis
factor-related  apoptosis-inducing  ligand,
Apo2L, and its receptors in myelodysplastic
syndrome: effects on in vitro hemopoiesis.
Blood 2001;98:3058-65.
22. Silverman LR, McKenzie DR, Peterson BL,
et al. Further analysis of trials with azaci-
tidine  in  patients  with  myelodysplastic
syndrome: studies 8421, 8921, and 9221 by
the Cancer and Leukemia Group B J Clin
Oncol 2006;24:3895-903.
23. Issa JP, Garcia-Manero G, Giles FJ, et al.
Phase 1 study of low-dose prolonged expo-
sure  schedules  of  the  hypomethylating
agent 5-aza-2'-deoxycytidine (decitabine)
in  hematopoietic  malignancies.  Blood
2004;103:1635-40.
24. Kantarjian H, Oki Y, Garcia-Manero G, et
al.  Results  of  a  randomized  study  of  3
schedules of low-dose decitabine in high-
er-risk  myelodysplastic  syndrome  and
chronic myelomonocytic leukemia. Blood
2007;109:52-7.
25. List A, Kurtin S, Roe DJ, et al. Efficacy of
lenalidomide  in  myelodysplastic  syn-
dromes. N Engl J Med 2005;352:549-57.
26. List  A,  Dewald  G,  Bennett  J,  et  al.
Lenalidomide in the myelodysplastic syn-
drome  with  chromosome  5q  deletion.  N
Engl J Med 2006;355:1456-65.
27. Raza  A,  Reeves  JA,  Feldman  EJ,  et  al.
Phase 2 study of lenalidomide in transfu-
sion-dependent,  low-risk,  and  intermedi-
ate-1 risk myelodysplastic syndromes with
karyotypes other than deletion 5q. Blood
2008;111:86-93.
28. Young NS, Maciejewski J. The pathophysi-
ology of acquired aplastic anemia. N Engl J
Med 1997;336:1365-72.
29. Kitagawa  M,  Saito  I,  Kuwata  T,  et  al.
Overexpression  of  tumor  necrosis  factor
(TNF)-alpha and interferon (IFN)-gamma
by bone marrow cells from patients with
myelodysplastic  syndromes.  Leukemia
1997;11:2049-54.
30. Molnar L, Berki T, Hussain A, Nemeth P,
Losonczy  H.  The  role  of  TNF-alpha  in
myelodysplastic  syndrome:  immunosero-
logic  and  immunohistochemical  studies.
Orv Hetil 2000;141:1807-11.
31. Selleri C, Maciejewski JP, Catalano L, et al.
Effects  of  cyclosporine  on  hematopoietic
and  immune  functions  in  patients  with
hypoplastic myelodysplasia: in vitro and in
vivo studies. Cancer 2002;95:1911-22.
32. Molldrem JJ, Jiang YZ, Stetler-Stevenson
M,  et  al.  Haematological  response  of
patients with myelodysplastic syndrome to
antithymocyte globulin is associated with
a loss of lymphocyte-mediated inhibition
of CFU-GM and alterations in T-cell recep-
tor Vbeta profiles. Br J Haematol 1998;102:
1314-22.
33. Kochenderfer JN, Kobayashi S, Wieder ED,
et  al.  Loss  of  T-lymphocyte  clonal  domi-
nance  in  patients  with  myelodysplastic
syndrome responsive to immunosuppres-
sion. Blood 2002;100:3639-45.
34. Epperson  DE,  Nakamura  R,  Sauntha-
rarajah Y, et al. Oligoclonal T cell expan-
sion  in  myelodysplastic  syndrome:  evi-
dence for an autoimmune process. Leuk
Res 2001;25:1075-83.
35. Kook H, Zeng W, Guibin C, et al. Increased
cytotoxic T cells with effector phenotype in
aplastic anemia and myelodysplasia. Exp
Hematol 2001;29:1270-7.
36. Baumann  I,  Scheid  C,  Koref  MS,  et  al.
Autologous  lymphocytes  inhibit  hemo-
poiesis  in  long-term  culture  in  patients
with  myelodysplastic  syndrome.  Exp
Hematol 2002;30:1405-11.
37. Epling-Burnette  PK,  Painter  JS,  Rollison
DE, et al. Prevalence and clinical associa-
tion  of  clonal  T-cell  expansions  in
myelodysplastic  syndrome.  Leukemia
2007;21:659-67.
38. Sloand  EM,  Rezvani  K.  The  role  of  the
immune system in myelodysplasia: impli-
cations  for  therapy.  Semin  Hematol.
2008;45:39-48.
39. Sloand EM, Mainwaring L, Fuhrer M, et al.
Preferential suppression of trisomy 8 com-
pared  with  normal  hematopoietic  cell
growth  by  autologous  lymphocytes  in
patients  with  trisomy  8  myelodysplastic
syndrome. Blood 2005;106:841-51.
40. Sloand EM, Kim S, Fuhrer M, et al. Fas-
mediated apoptosis is important in regu-
lating cell replication and death in trisomy
8 hematopoietic cells but not in cells with
other  cytogenetic  abnormalities.  Blood
2002;100:4427-32.
41. Chen  G,  Zeng  W,  Miyazato  A,  et  al.
Distinctive  gene  expression  profiles  of
CD34 cells from patients with myelodys-
plastic syndrome characterized by specific
chromosomal  abnormalities.  Blood  2004;
104:4210-8.
42. Sloand EM, Pfannes L, Chen G, et al. CD34
cells  from  patients  with  trisomy  8
myelodysplastic syndrome (MDS) express
early  apoptotic  markers  but  avoid  pro-
grammed  cell  death  by  up-regulation  of
antiapoptotic  proteins.  Blood  2007;
109:2399-405.
43. Dunn DE, Tanawattanacharoen P, Boccuni
P, et al. Paroxysmal nocturnal hemoglobin-
uria cells in patients with bone marrow
failure syndromes. Ann Intern Med 1999;
131:401-8.
44. Wang H, Chuhjo T, Yasue S, et al. Clinical
significance  of  a  minor  population  of
paroxysmal  nocturnal  hemoglobinuria-
type  cells  in  bone  marrow  failure  syn-
drome. Blood 2002;100:3897-902.
45. Sugimori C, Chuhjo T, Feng X, et al. Minor
population of CD55-CD59- blood cells pre-
dicts  response  to  immunosuppressive
therapy  and  prognosis  in  patients  with
aplastic anemia. Blood 2006;107:1308-14.
46. Murakami  Y,  Kosaka  H,  Maeda  Y,  et  al.
Article
[page 7][page 8] [Hematology Reports 2010; 2:e1]
Inefficient response of T lymphocytes to
glycosylphosphatidylinositol  anchor-nega-
tive cells: implications for paroxysmal noc-
turnal  hemoglobinuria.  Blood  2002;100:
4116-22.
47. Nagakura S, Ishihara S, Dunn DE, et al.
Decreased susceptibility of leukemic cells
with PIG-A mutation to natural killer cells
in vitro. Blood 2002;100:1031-7.
48. Luzzatto L, Bessler M, Rotoli B. Somatic
mutations in paroxysmal nocturnal hemo-
globinuria:  a  blessing  in  disguise?  Cell
1997;88:1-4.
49. Parker  C,  Omine  M,  Richards  S,  et  al.
Diagnosis and management of paroxysmal
nocturnal  hemoglobinuria.  Blood  2005;
106:3699-709.
50. Zou  JX,  Rollison  DE,  Boulware  D,  et  al.
Altered  naive  and  memory  CD4+  T-cell
homeostasis  and  immunosenescence
characterize  younger  patients  with
myelodysplastic  syndrome.  Leukemia
2009.
51. Goronzy  JJ,  Weyand  CM.  Rheumatoid
arthritis. Immunol Rev 2005;204:55-73.
52. Krupica  T  Jr.,  Fry  TJ,  Mackall  CL.  Auto-
immunity during lymphopenia: a two-hit
model. Clin Immunol 2006;120:121-8.
53. Kordasti SY, Afzali B, Lim Z, et al. IL-17-
producing CD4(+) T cells, pro-inflamma-
tory cytokines and apoptosis are increased
in low risk myelodysplastic syndrome. Br J
Haematol 2009;145:64-72.
54. Cheson BD, Bennett JM, Kantarjian H, et
al.  Report  of  an  international  working
group to standardize response criteria for
myelodysplastic  syndromes.  Blood  2000;
96:3671-4.
55. Cheson BD, Greenberg PL, Bennett JM, et
al.  Clinical  application  and  proposal  for
modification of the International Working
Group (IWG) response criteria in myelo-
dysplasia. Blood 2006;108:419-25.
56. Luger S, Sacks N. Bone marrow transplan-
tation for myelodysplastic syndrome--who?
when?  and  which?  Bone  Marrow
Transplant 2002;30:199-206.
57. Marsh J, Schrezenmeier H, Marin P, et al.
Prospective randomized multicenter study
comparing  cyclosporin  alone  versus  the
combination  of  antithymocyte  globulin
and cyclosporin for treatment of patients
with nonsevere aplastic anemia: a report
from  the  European  Blood  and  Marrow
Transplant  (EBMT)  Severe  Aplastic
Anaemia  Working  Party.  Blood  1999;
93:2191-5.
58. Bacigalupo A, Bruno B, Saracco P, et al.
Antilymphocyte  globulin,  cyclosporine,
prednisolone,  and  granulocyte  colony-
stimulating factor for severe aplastic ane-
mia: an update of the GITMO/EBMT study
on 100 patients. European Group for Blood
and  Marrow  Transplantation  (EBMT)
Working Party on Severe Aplastic Anemia
and  the  Gruppo  Italiano  Trapianti  di
Midollo Osseo (GITMO). Blood 2000; 95:
1931-4.
59. Young N, Griffith P, Brittain E, et al. A mul-
ticenter trial of antithymocyte globulin in
aplastic  anemia  and  related  diseases.
Blood 1988;72:1861-9.
60. Mohty M. Mechanisms of action of antithy-
mocyte  globulin:  T-cell  depletion  and
beyond. Leukemia 2007;21:1387-94.
61. Bonnefoy-Berard  N,  Vincent  C,  Revillard
JP. Antibodies against functional leukocyte
surface  molecules  in  polyclonal  antilym-
phocyte  and  antithymocyte  globulins.
Transplantation 1991;51:669-73.
62. Michallet MC, Preville X, Flacher M, et al.
Functional antibodies to leukocyte adhe-
sion molecules in antithymocyte globulins.
Transplantation 2003;75:657-62.
63. Zand MS, Vo T, Huggins J, et al. Polyclonal
rabbit antithymocyte globulin triggers B-
cell and plasma cell apoptosis by multiple
pathways.  Transplantation  2005;79:1507-
15.
64. Haidinger M, Geyeregger R, Poglitsch M,
et  al.  Antithymocyte  globulin  impairs  T-
cell/antigen-presenting  cell  interaction:
disruption of immunological synapse and
conjugate  formation.  Transplantation
2007;84:117-21.
65. Lopez M, Clarkson MR, Albin M, et al. A
novel mechanism of action for anti-thymo-
cyte  globulin:  induction  of  CD4+CD25+
Foxp3+  regulatory  T  cells.  J  Am  Soc
Nephrol 2006;17:2844-53.
66. Lan  F,  Zeng  D,  Higuchi  M,  et  al.
Predominance of NK1.1+TCR alpha beta+
or DX5+TCR alpha beta+ T cells in mice
conditioned  with  fractionated  lymphoid
irradiation  protects  against  graft-versus-
host disease: "natural suppressor" cells. J
Immunol 2001;167:2087-96.
67. Killick  SB,  Marsh  JC,  Gordon-Smith  EC,
Sorlin L, Gibson FM. Effects of antithymo-
cyte globulin on bone marrow CD34+ cells
in  aplastic  anaemia  and  myelodysplasia.
Br J Haematol 2000;108:582-91.
68. Killick  SB,  Cox  CV,  Marsh  JC,  et  al.
Mechanisms  of  bone  marrow  progenitor
cell apoptosis in aplastic anaemia and the
effect of anti-thymocyte globulin: exami-
nation of the role of the Fas-Fas-L interac-
tion. Br J Haematol 2000;111:1164-9.
69. Molldrem  JJ,  Leifer  E,  Bahceci  E,  et  al.
Antithymocyte  globulin  for  treatment  of
the bone marrow failure associated with
myelodysplastic  syndromes.  Ann  Intern
Med 2002;137:156-63.
70. Saunthararajah Y, Nakamura R, Nam JM,
et al. HLA-DR15 (DR2) is overrepresented
in myelodysplastic syndrome and aplastic
anemia and predicts a response to immu-
nosuppression  in  myelodysplastic  syn-
drome. Blood 2002;100:1570-4.
71. Yazji S, Giles FJ, Tsimberidou AM, et al.
Antithymocyte globulin (ATG)-based ther-
apy in patients with myelodysplastic syn-
dromes. Leukemia 2003;17:2101-6.
72. Steensma DP, Dispenzieri A, Moore SB, et
al. Antithymocyte globulin has limited effi-
cacy and substantial toxicity in unselected
anemic patients with myelodysplastic syn-
drome. Blood 2003;101:2156-8.
73. Stadler M, Germing U, Kliche KO, et al. A
prospective, randomised, phase II study of
horse  antithymocyte  globulin  vs  rabbit
antithymocyte globulin as immune-modu-
lating  therapy  in  patients  with  low-risk
myelodysplastic  syndromes.  Leukemia
2004;18:460-5.
74. Broliden  PA,  Dahl  IM,  Hast  R,  et  al.
Antithymocyte globulin and cyclosporine A
as combination therapy for low-risk non-
sideroblastic  myelodysplastic  syndromes.
Haematologica 2006;91:667-70.
75. Lim  ZY,  Pearce  L,  Ho  AY,  et  al.  Delayed
attainment of full donor chimaerism fol-
lowing  alemtuzumab-based  reduced-
intensity  conditioning  haematopoeitic
stem cell transplantation for acute myeloid
leukaemia and myelodysplastic syndromes
is associated with improved outcomes. Br
J Haematol 2007;138:517-26.
76. Sloand  EM,  Wu  CO,  Greenberg  P,  et  al.
Factors affecting response and survival in
patients with myelodysplasia treated with
immunosuppressive therapy. J Clin Oncol
2008;26:2505-11.
77. Molldrem JJ, Caples M, Mavroudis D, et al
Antithymocyte  globulin  for  patients  with
myelodysplastic syndrome. Br J Haematol
1997;99:699-705.
78. Kapustin SI, Popova TI, Lyschov AA, et al.
HLA-DR2  Frequency  increase  in  severe
aplastic anemia patients is mainly attrib-
uted to the prevalence of DR15 subtype.
Pathol Oncol Res 1997;3:106-8.
79. Nakao S, Takamatsu H, Chuhjo T, et al.
Identification  of  a  specific  HLA  class  II
haplotype strongly associated with suscep-
tibility to cyclosporine-dependent aplastic
anemia. Blood 1994;84:4257-61.
80. Maciejewski JP, Follmann D, Nakamura R,
et al. Increased frequency of HLA-DR2 in
patients with paroxysmal nocturnal hemo-
globinuria  and  the  PNH/aplastic  anemia
syndrome. Blood 2001;98:3513-9.
81. Killick SB, Mufti G, Cavenagh JD, et al. A
pilot  study  of  antithymocyte  globulin
(ATG) in the treatment of patients with
'low-risk'  myelodysplasia.  Br  J  Haematol
2003;120:679-84.
82. Frickhofen N, Heimpel H, Kaltwasser JP,
Schrezenmeier H. Antithymocyte globulin
with or without cyclosporin A: 11-year fol-
low-up  of  a  randomized  trial  comparing
treatments  of  aplastic  anemia.  Blood
Article[Hematology Reports 2010; 2:e1]
2003;101:1236-42.
83. Jonasova A, Neuwirtova R, Cermak J, et al.
Cyclosporin A therapy in hypoplastic MDS
patients and certain refractory anaemias
without  hypoplastic  bone  marrow.  Br  J
Haematol 1998;100:304-9.
84. Catalano  L,  Selleri  C,  Califano  C,  et  al.
Prolonged  response  to  cyclosporin-A  in
hypoplastic refractory anemia and correla-
tion with in vitro studies. Haematologica
2000;85:133-8.
85. Atoyebi W, Bywater L, Rawlings L, et al.
Treatment  of  myelodysplasia  with  oral
cyclosporin.  Clin  Lab  Haematol  2002;24:
211-4.
86. Shimamoto T, Tohyama K, Okamoto T, et
al. Cyclosporin A therapy for patients with
myelodysplastic  syndrome:  multicenter
pilot  studies  in  Japan.  Leuk  Res  2003;
27:783-8.
87. Dixit  A,  Chatterjee  T,  Mishra  P,  et  al.
Cyclosporin  A  in  myelodysplastic  syn-
drome: a preliminary report. Ann Hematol
2005;84:565-8.
88. Chen SC, Jiang B, Da WM, Gong M, Guan
M. Curative effects of cyclosporin A thera-
py  upon  myelodysplastic  syndrome.
Zhonghua Yi Xue Za Zhi 2006;86:2711-5.
89. Ishikawa T, Tohyama K, Nakao S, et al. A
prospective study of cyclosporine A treat-
ment of patients with low-risk myelodys-
plastic  syndrome:  presence  of  CD55(-)
CD59(-)  blood  cells  predicts  platelet
response. Int J Hematol 2007;86:150-7.
90. Cai  W,  Hu  L,  Foulkes  JG.  Transcription-
modulating drugs: mechanism and selec-
tivity. Curr Opin Biotechnol 1996;7:608-15.
91. Shimamoto  T,  Iguchi  T,  Ando  K,  et  al.
Successful  treatment  with  cyclosporin  A
for  myelodysplastic  syndrome  with  ery-
throid  hypoplasia  associated  with  T-cell
receptor  gene  rearrangements.  Br  J
Haematol 2001;114:358-61.
Article
[page 9]